Skip to main content
Premium Trial:

Request an Annual Quote

Farfield Scientific, Aussie University to Co-Develop Protein-Analysis Tools

NEW YORK (GenomeWeb News) — Farfield Scientific will partner with Australia’s Monash University to develop biosensor surfaces to analyze protein functioning, UK-based Farfield said today.
The company said the aim of the collaboration, which has received funding from the Australian Research Council, is to commercialize membrane-mimetic biosensor surfaces to analyze the structure and functioning of membrane-associating peptides and proteins.
Monash project leader Mari-Isabel Aquilar said the collaboration with the school’s Department of Biochemistry and Molecular Biology will use Farfield’s AnaLight Bio2000 Dual Polarization Interferometry tool to analyze membrane surfaces, and develop and apply biosensor chips based on Monash’s IP for identifying new proteins and drug targets.
Farfield CEO Gerry Ronan said the research will create a bioanalytical toolkit that will “ultimately lead to an entirely new approach to structurally informed drug discovery.”

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.